Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 10 Issue 4, September 2016

Volume 10 Issue 4

In this issue...

• Platform biotechs harvest the fruits of independence

• Immuno-oncology: the rise of the checkpoint inhibitors

• Next-generation antibodies land string of deals

Cover image: Microscopy imaging of metastatic cancer cells. Nicola Ferrari, Thinkstock.

Platform biotechs

    Feature

  • News Feature |

    A trend toward outsourcing early-stage R&D and thriving capital markets over the past few years have helped platform biotechs remain independent and able to ink creative deals with pharma companies.

    • Chris Morrison
  • Profiles

  • Advertisement Feature |

    GRoK Technologies has harnessed decades of space-based research to develop 3D human tissue models proven to mimic the physiological responses of human organs, and has advanced technology for improving the quality, yield and long-term viability of adult stem cells for tissue engineering and regenerative medicine.

  • Advertisement Feature |

    Precision BioSciences is harnessing its next-generation genome editing platform, ARCUS, to develop a pipeline of cell-based immunotherapies for cancer and autoimmune disease, as well as gene therapies for rare genetic disorders. The company is looking for uniquely suited partners to aid in these efforts.

  • Advertisement Feature |

    co.don AG currently markets its regenerative therapy methods in Germany, where uptake is increasing among orthopedic surgeons, trauma surgeons and neurosurgeons.

  • Advertisement Feature |

    Plasticell is leveraging its innovative combinatorial screening technology for a broad range of cell and gene therapy applications, whereas spin-out Progenitor Therapeutics focuses on small-molecule regenerative drug discovery.

Checkpoint inhibitors

    Feature

  • News Feature |

    The clinical impact of checkpoint inhibitors and their anticipated position as linchpins of future cancer immunotherapy regimens has driven a wave of dealmaking. In this feature, we chart the development progress and major deals for the leading checkpoint inhibitors.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    With its innovative fusion cancer vaccine that greatly enhances the target specificity of T cells, Tokyo-based CyTIX is poised to take advantage of the biopharma industry’s increasing interest in next-generation cancer vaccines.

  • Advertisement Feature |

    Exicure is pioneering the development of spherical nucleic acid technology as a promising avenue of therapeutic development to strengthen and prolong the body’s natural immune defenses against a wide range of cancers.

  • Advertisement Feature |

    BeyondSpring Pharmaceuticals’ plinabulin demonstrates a multifaceted approach that targets immune and vascular aspects of tumor growth, resulting in immune-enhancing effects.

Next-generation antibodies

    Feature

  • News Feature |

    Progress in tackling technical challenges in the development of bispecific antibodies and emerging opportunities in the red-hot immuno-oncology space have catalyzed a flurry of dealmaking activity for bispecific platform companies.

    • Nick Taylor
  • Profiles

  • Advertisement Feature |

    Trianni has developed transgenic immunoglobulin mice capable of expressing the full human antibody repertoire, ideal for the discovery of new therapeutic antibody candidates.

Search

Quick links